Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30923125 | 1.00 | GPR119 (0.46) | GPR119HPGDRECQLEPHX1NR1H2 | |
| SCHEMBL23700689 | 1.00 | GPR119 (0.46) | GPR119HPGDRECQLEPHX1NR1H2 | |
| SCHEMBL31200554 | 0.92 | HPGD (0.46) | GPR119HPGDRECQLEPHX1NR1H2 | |
| SCHEMBL25425866 | 0.91 | GPR119 (0.46) | GPR119HPGDRECQLEPHX1NR1H2 | |
| SCHEMBL1135376 | 0.91 | NR1H2 (0.51) | GPR119HPGDNR1H2JAK2JAK1 | |
| SCHEMBL23663758 | 0.91 | NR1H2 (0.51) | GPR119HPGDNR1H2JAK2JAK1 | |
| SCHEMBL4900183 | 0.91 | NR1H2 (0.51) | GPR119HPGDNR1H2JAK2JAK1 | |
| SCHEMBL22010186 | 0.91 | NR1H2 (0.51) | GPR119HPGDNR1H2JAK2JAK1 | |
| SCHEMBL1135431 | 0.91 | NR1H2 (0.51) | GPR119HPGDNR1H2JAK2JAK1 | |
| SCHEMBL1135375 | 0.91 | NR1H2 (0.51) | GPR119HPGDNR1H2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015353-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250353830-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4562009-A1 | NOVEL COMPOUNDS | AC Immune SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4558499-A1 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| EP-4531858-A1 | NOVEL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| EP-4433459-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| US-20210171518-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-06-10 | — | — | US | disclosed |
| EP-3802549-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10899755-B2 | Benzothiazole compounds and uses thereof | INCYTE CORPORATION (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200048241-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-02-13 | — | — | US | disclosed |
| WO-2019228940-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-05 | — | — | WO | disclosed |
| EP-3548495-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018102384-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | GPR119 343/4885HPGD 1295/4885RECQL 1709/4885 |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | CAMK1, CAMKK1, CAMK1D | GPR119 1733/4885HPGD 1387/4885RECQL 1430/4885 |
| US-20260015353-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NOD2 | GPR119 280/4885HPGD 1278/4885RECQL 886/4885 |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | GPR119 1733/4885HPGD 1387/4885RECQL 1430/4885 |
| US-10899755-B2 | Benzothiazole compounds and uses thereof | PDXK, PCK1, HIPK1 | GPR119 1886/4885HPGD 174/4885RECQL 961/4885 |
| US-20210171518-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | PDXK, PCK1, HIPK1 | GPR119 1886/4885HPGD 174/4885RECQL 961/4885 |
| US-20200048241-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | PDXK, PCK1, HIPK1 | GPR119 1886/4885HPGD 174/4885RECQL 961/4885 |
| US-20250353830-A1 | NOVEL COMPOUNDS | UQCRB, CCNB3, C5 | GPR119 366/4885HPGD 4168/4885RECQL 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.